Millie
your market intelligence analyst
Search Results
116 results
Your search is now limited to «Clinical Trials» expert search.
PR Newswire 09/19/2019 08:00
The Phase 2a study enrolled patients with classic CAH accompanied by elevated androgens at baseline who were treated with tildacerfont once-daily over 12 weeks, resulting in clinically relevant reductions in key parameters.
More from PR Newswire:
ClinicalTrials.gov 09/17/2019 07:03
Condition : Acute Ischemic Stroke Interventions : Drug: LT3001 Drug Product; Drug: Placebo Sponsor : Lumosa Therapeutics Co., Ltd. Not yet recruiting.
More from ClinicalTrials.gov:
Alnylam initiates APOLLO-B phase 3 study of patisiran for treatment of transthyretin amyloidosis with cardiomyopathy.
More from Pharmaceutical Business Review:
Business Wire 09/16/2019 16:30
FSHD Phase 2 Trial Design The two-part Phase 2 clinical trial was designed to evaluate ACE-083 in FSHD patients with muscle weakness in the biceps brachii (BB) and the tibialis anterior (TA), a muscle in the lower ...
More from Business Wire:
FeedNavigator (EU) 09/16/2019 09:07
The study was registered with Clinicaltrials.gov, NCT03071263.
More from FeedNavigator (EU):
GlobeNewswire 09/16/2019 07:00
Akcea and Ionis also plan to initiate the Phase 3 program for AKCEA-TTR-LRx later this year.
More from GlobeNewswire:
FiercePharmaManufacturing 09/06/2019 12:05
The British drugmaker aims to “increase the scope” of its physician marketing after phase 3 trial data showed Farxiga cut the risk of cardiovascular death or hospitalization in heart failure patients by 26% over standard of care—regardless of whether those patients had Type 2 diabetes.
More from FiercePharmaManufacturing:
Pharmafile 09/02/2019 06:31
The findings of the study showed that Entresto reduced the total (first and recurrent) heart failure hospitalisations and cardiovascular (CV) death experienced by patients by 13%, falling just short of the primary endpoint.
More from Pharmafile:
pharmaphorum 08/29/2019 05:43
AstraZeneca has been on a hot streak of trial successes recently, with the latest win being in a late-stage study for a potential lupus drug that looked dead and buried after a major trial flop last year.
More from pharmaphorum:
Pulmonary Hypertension News 08/28/2019 08:00
A Phase 2 clinical trial for levosimendan, a potential treatment for pulmonary hypertension (PH) and heart failure with preserved ejection fraction (PH-HFpEF), will soon have three more active sites for participant enrollment, Tenax Therapeutics announced.
More from Pulmonary Hypertension News:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications